Key facts
- It has raised $95.0M across 2 recorded rounds; the latest was PIPE ($95.0M) in Feb 2021.
- Gemini Therapeutics has filed 1 Form D with the SEC, most recently May 2016 ($2.0M sold to 4 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for Gemini Therapeutics
Create free account
No card required
Funding rounds
2 roundsFeb 2021PIPE$95.0M▮
About Gemini Therapeutics
- Industry
- Drug Discovery
PA Mark — not yet priced
Gemini Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Gemini Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Gemini Therapeutics in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.